Posts

Priavoid’s Alzheimer’s pill misses its Phase 2 primary efficacy target

Priavoid’s Phase 2 PRImus-AD trial of PRI-002, an oral peptide designed to break apart amyloid-beta oligomers, did not meet its primary efficacy endpoint: change in Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 48. The trial enrolled 304 people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, randomized to 300 mg or 600 mg of PRI-002 daily or placebo. The company reported a favorable safety and tolerability profile, meeting the trial’s primary safety endpoint. Some secondary and later exploratory analyses showed numerical differences favoring treatment, but most were not statistically significant. At Week 72, an exploratory ADAS-Cog13 analysis in the per-protocol group showed 35.9% less decline versus placebo (p=0.022); the company says the full dataset is expected in 2027. The results are an early-stage signal, not evidence that PRI-002 meaningfully slows Alzheimer’s progression. The primary efficacy miss means any possible benefit needs c...

Lilly and Stipple Bio announce oncology deal worth up to $5.9 billion

Emerging biotech hubs compete on more than cost

Flagship commits £100 million to launch AI biotech lab in London

Sofinnova closes €725M fund for late-stage life sciences companies

CG Oncology reports strong Phase 3 bladder cancer results

J&J to acquire Ollin Biosciences for up to $3.33 billion

Helus Pharma shares fall despite positive Phase 3 depression results

Roche enters the SERD market with FDA approval for advanced breast cancer

Biogen backs TRIM21-based protein degraders in potential $411 million TRIMTECH deal

Petosemtamab’s first-line HNSCC results could reshape treatment sequencing

FDA clears MiniMed Fit, a new seven-day tubeless insulin pump

OpenAI expands ChatGPT for Healthcare with AI agents and Elation Health plugin